NexImmune, Inc. (NEXI)

0,4251 +0,0185 (+4,55%) Börsenschluss: 04:00PM EST

NexImmune, Inc.

9119 Gaither Road
Gaithersburg, MD 20877
United States
301 825 9810
https://www.neximmune.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 74

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Ms. Kristi Jones R.Ph.	CEO, Pres & Director	520,87k	N/A	1963
Mr. John Trainer M.B.A.	Chief Financial Officer	514,67k	N/A	1974
Dr. Jerome Bernard Zeldis M.D., Ph.D.	Exec. VP of R&D	405,79k	N/A	1950
Dr. Robert Douglas Knight M.D.	Chief Medical Officer	454,77k	N/A	1951
Dr. Mathias Oelke Ph.D.	Chief Scientific Officer	N/A	N/A	1969
Mr. Karen Haslbeck	Head of HR	N/A	N/A	N/A
Dr. Daniel P. Bednarik	Sr. VP of Molecular Engineering & Protein Design	N/A	N/A	N/A
Mr. Chad Rubin	Sr. VP of Corp. Affairs	N/A	N/A	N/A
Dr. Jack A. Ragheb M.D., Ph.D.	Sr. VP of Translational Science	N/A	N/A	N/A
Mr. Matthew Schiller	Head of Bus. Devel.	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

Corporate Governance

NexImmune, Inc.s ISS Governance QualityScore, Stand 28. Januar 2023, lautet 9. Die grundlegenden Scores sind Audit: 9, Vorstand: 9, Shareholderrechte: 8, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.